| Multiple Sclerosis
Ampyra vs Lemtrada
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis.Deep comparison between: Ampyra vs Lemtrada with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLemtrada has a higher rate of injection site reactions vs Ampyra based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lemtrada but not Ampyra, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ampyra
Lemtrada
At A Glance
Oral
Twice daily
Potassium channel blocker
IV infusion
Annual treatment courses
Anti-CD52 monoclonal antibody
Indications
- Multiple Sclerosis
- Multiple Sclerosis
Dosing
Multiple Sclerosis 10 mg tablet twice daily approximately 12 hours apart; do not exceed 10 mg twice daily; swallow tablets whole; may be taken with or without food.
Multiple Sclerosis First course: 12 mg/day IV infusion on 5 consecutive days; second course: 12 mg/day on 3 consecutive days 12 months after first course; subsequent courses: 12 mg/day on 3 consecutive days as needed, at least 12 months after the last prior dose. Premedicate with high-dose corticosteroids for the first 3 days of each course; administer antiviral prophylaxis starting on the first day of each course for a minimum of 2 months or until CD4+ count >= 200 cells/microliter.
Contraindications
- History of seizure
- Moderate or severe renal impairment (CrCl <=50 mL/min)
- History of hypersensitivity to AMPYRA or 4-aminopyridine, including anaphylaxis
- Known hypersensitivity or anaphylactic reaction to alemtuzumab or any excipient
- HIV infection
- Active infection
Adverse Reactions
Most common (>=2%) Urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, pharyngolaryngeal pain
Serious Seizures, anaphylaxis
Postmarketing Vomiting, vertigo
Most common (>=10%) Rash, headache, pyrexia, nasopharyngitis, nausea, urinary tract infection, fatigue, insomnia, upper respiratory tract infection, herpes viral infection, urticaria, pruritus, thyroid gland disorders, fungal infection, arthralgia, pain in extremity, back pain, diarrhea, sinusitis, oropharyngeal pain, paresthesia, dizziness, abdominal pain, flushing, vomiting
Serious Autoimmunity, infusion reactions, stroke and cervicocephalic arterial dissection, malignancies, immune thrombocytopenia, glomerular nephropathies including anti-GBM disease, thyroid disorders, other autoimmune cytopenias, autoimmune hepatitis, hemophagocytic lymphohistiocytosis, adult onset Still's disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, acquired hemophilia A, immune-mediated colitis, infections, progressive multifocal leukoencephalopathy, acute acalculous cholecystitis, pneumonitis
Postmarketing Acquired hemophilia A, neutropenia, thrombocytopenia, thrombotic thrombocytopenic purpura, stroke (hemorrhagic and ischemic), cervicocephalic arterial dissection, cholecystitis, immune-mediated colitis, autoimmune hepatitis, viral hepatitis, opportunistic infections, progressive multifocal leukoencephalopathy, vasculitis, Guillain-Barre syndrome, hemophagocytic lymphohistiocytosis, sarcoidosis, adult onset Still's disease, autoimmune encephalitis, myasthenia gravis, Lambert-Eaton myasthenic syndrome, pulmonary alveolar hemorrhage, alopecia
Pharmacology
Dalfampridine is a broad spectrum potassium channel blocker that increases conduction of action potentials in demyelinated axons through inhibition of potassium channels; the mechanism by which it improves walking in MS has not been fully elucidated.
Alemtuzumab is a humanized IgG1 kappa monoclonal antibody that binds to CD52, a cell surface antigen on T and B lymphocytes, natural killer cells, monocytes, and macrophages, resulting in antibody-dependent cellular cytolysis and complement-mediated lysis; the precise mechanism by which this exerts therapeutic effects in MS is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ampyra
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
Lemtrada
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Ampyra
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Lemtrada
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Ampyra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Lemtrada
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AmpyraView full Ampyra profile
LemtradaView full Lemtrada profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.